Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Conditions:   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Urothelial Carcinoma;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Urethral Cancer;   Urethral Urothelial CarcinomaInterventions:   Drug: Pembrolizumab;   Drug: Docetaxel;   Drug: Gemcitabine HydrochlorideSponsors:   University of California, Davis;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.Not yet recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials